Holen Sie sich die Stockscreener-App
4.53
5.10%
0.22
Handel nachbörslich:
4.51
-0.02
-0.44%
Schlusskurs vom Vortag:
$4.31
Offen:
$4.4
24-Stunden-Volumen:
2.55M
Relative Volume:
1.18
Marktkapitalisierung:
$872.03M
Einnahmen:
$14.08M
Nettoeinkommen (Verlust:
$-33.50M
KGV:
-25.83
EPS:
-0.1754
Netto-Cashflow:
$-39.72M
1W Leistung:
+6.59%
1M Leistung:
-1.52%
6M Leistung:
+4.86%
1J Leistung:
+34.42%
1-Tages-Spanne:
$4.385
$4.64
1-Wochen-Bereich:
$4.14
$4.64
52-Wochen-Spanne:
$2.705
$5.10
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Firmenname
Arbutus Biopharma Corp
Sektor
Branche
Telefon
604-419-3200
Adresse
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.53 | 829.68M | 14.08M | -33.50M | -39.72M | -0.1754 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-02-02 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Eingeleitet | Jefferies | Hold |
| 2020-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-27 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2020-07-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-03-06 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | Bestätigt | B. Riley FBR | Buy |
| 2019-10-04 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | Hochstufung | Wedbush | Underperform → Neutral |
| 2018-10-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-07-06 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2018-03-19 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | Bestätigt | Wedbush | Outperform |
| 2016-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
Alle ansehen
Arbutus Biopharma Corp Aktie (ABUS) Neueste Nachrichten
Arbutus Biopharma Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Arbutus: Q4 Earnings Snapshot - theheraldreview.com
Arbutus Biopharma Hits Day Low of $4.21 Amid Price Pressure - Markets Mojo
Arbutus Biopharma (ABUS) Q3 Loss And Revenue Drop Challenge Bullish Profitability Narratives - simplywall.st
Arbutus Biopharma 2025 Financials: Reduced Annual Loss, Revenue GrowthNews and Statistics - IndexBox
Arbutus Biopharma Corporation (ABUS) Form 8-K Filing Details, Key Financials, and Company Information - Minichart
Arbutus Biopharma earnings beat by $0.02, revenue topped estimates - Investing.com
Arbutus Biopharma 2025 Annual Report: Clinical Pipeline, Patent Litigation, and Strategic Outlook - Minichart
Arbutus Biopharma Corp expected to post a loss of 4 cents a shareEarnings Preview - TradingView
Arbutus Biopharma (ABUS) Misses EPS Estimates but Exceeds Revenue Expectations - GuruFocus
Arbutus: Fourth Quarter Financial Results Overview - Bitget
Arbutus Biopharma (NASDAQ:ABUS) Posts Earnings Results - MarketBeat
Arbutus Biopharma (Nasdaq: ABUS) trims 2025 loss after $2.25B Moderna settlement - Stock Titan
Moderna settlement reshapes Arbutus Biopharma (ABUS) with $950M payout - Stock Titan
Arbutus' imdusiran nets two more HBV functional cures; Q3 2026 capital return eyed after $2.25B deal - Stock Titan
Market Moves: Is Arbutus Biopharma Corporation attractive at current valuation2026 Bull vs Bear & AI Based Trade Execution Alerts - baoquankhu1.vn
Arbutus Biopharma (ABUS) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Moderna to pay about $1 billion to settle Arbutus litigation - MSN
Foursixthree Capital LP Has $8.99 Million Stake in Arbutus Biopharma Corporation $ABUS - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Shares Down 8.4%Time to Sell? - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
Moderna Settles Patent Litigation with Arbutus et al. - JD Supra
Arbutus Biopharma Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
9 Biotech Stocks Trading Far Below Fair Value With Up to 250% Upside Potential - Investing.com
Moderna reaches $950 million settlement with Arbutus and Genevant over patent litigation - Investing.com
Moderna to Pay About $1 Billion to Settle Arbutus Litigation - Claims Journal
Here's Arbutus Biopharma's share of $950M Moderna settlement - The Business Journals
Arbutus Biopharma (NASDAQ:ABUS) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Arbutus Biopharma (ABUS) Reaches Settlement with Moderna Over Pa - GuruFocus
Chardan reiterates Arbutus Biopharma stock rating on Moderna deal By Investing.com - Investing.com Canada
MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS - Finviz
Chardan reiterates Arbutus Biopharma stock rating on Moderna deal - Investing.com
ABUS: Key Developments and Market Impact - GuruFocus
Moderna's $950 Million Settlement Clears Legal Overhang, Stock SoarsModerna (NASDAQ:MRNA) - Benzinga
Moderna to pay about US$1 bil to settle Arbutus litigation - The Edge Malaysia
Genevant and Arbutus agree $2.25 billion global settlement with Moderna - The Pharma Letter
Why Box Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Moderna Shares Rise 16% After Company Enters Settlement Agreement With Arbutus Biopharma, Genevant Sciences - Bitget
Moderna To Pay At Least $950M To End COVID-19 Vax IP Fight - Law360
Moderna to pay Genevant Sciences and Arbutus Biopharma up to $2.25 billion in global patent settlement - PharmaLive
Moderna agrees to pay nearly $1B to settle Covid vaccine patent battle - The Business Journals
Arbutus Biopharma (ABUS) and Genevant Reach $2.25 Billion Settle - GuruFocus
Arbutus Biopharma Reaches Transformative Global Settlement With Moderna - TipRanks
Roivant, Arbutus Biopharma stocks surges on $2.25B Moderna settlement - Investing.com
Roivant's Genevant and Arbutus reach $2.25 billion settlement with Moderna - StreetInsider
Arbutus Biopharma (Nasdaq: ABUS) details $2.25B Moderna patent settlement - Stock Titan
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna - GlobeNewswire
Moderna Royalty Loss Raises Covid-Shot Trial Stakes (Correct) - Bloomberg Law News
Arbutus Biopharma wins partial summary judgment on Moderna defenses; enablement dispute to go to jury - TradingView
Key patent ruling boosts Arbutus Biopharma (NASDAQ: ABUS) in Moderna LNP case - Stock Titan
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna - Intellectia AI
Finanzdaten der Arbutus Biopharma Corp-Aktie (ABUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):